胰腺癌新辅助治疗的现状与展望

Progress of neoadjuvant therapy for pancreatic cancer

传统综合治疗在改善胰腺癌疗效上的作用仍十分有限。鉴于乳腺癌、结直肠癌新辅助治疗的良好结果,胰腺癌新辅助治疗逐渐成为关注的热点。与术后辅助治疗相比,新辅助治疗有助于改善根治切除率,患者对放化疗的耐受性更好。但是,目前尚缺少胰腺癌新辅助治疗后手术与直接手术间比较的随机对照研究来评价新辅助治疗的疗效。因此需要进一步的高质量的循证医学证据来证实患者能否从新辅助治疗中获益,以期提高胰腺癌的治疗水平。

The results of multimodal approaches of pancreatic cancer are still disappointing.Neoadjuvant therapy has been approved in breast cancer and colorectal cancer,and its value has come to be highlighted in pancreatic cancer.In contrast to the usual adjuvant therapy after surgery,neoadjuvant therapy is beneficial for resection of pancreatic cancer with free margins and for lower lymphatic spread.Another advantage of neoadjuvant therapy is the better tolerability to multimodal treatment.Whereas,few prospective randomized controlled clinical trials（RCTs） on the surgical therapy after the neoadjuvant therapy and the surgical therapy alone has been done to show the convincing benefit from neoadjuvant therapy.Therefore more high-level evidence-based medical researches are expected to evaluate the value of neoadjuvant therapy of pancreatic cancer.